Immuneering Showcases Promising Phase 2 Pancreatic Cancer Data for Atebimetinib Combination
Reuters
Nov 22
Immuneering Showcases Promising Phase 2 Pancreatic Cancer Data for Atebimetinib Combination
Immuneering Corporation has shared new data from its ongoing Phase 2a study evaluating atebimetinib in combination with modified gemcitabine and nab-paclitaxel (mGnP) for first-line treatment of pancreatic cancer. The study reports a median progression-free survival (mPFS) of 9.6 months for the atebimetinib + mGnP combination in a broad patient population. By comparison, benchmark mPFS values for standard regimens are reported as 5.5 months for GnP, 6.4 months for FOLFIRINOX, and 7.4 months for NALIRIFOX. At nine months, progression-free survival probability was 53% [31, 71] for patients receiving atebimetinib + mGnP. The median follow-up for overall survival was 9.0 months as of the August 26, 2025 data cutoff. No head-to-head clinical trials have been conducted, and differences exist between trial designs and subject characteristics. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief on November 21, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.